TuHURA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update
Rhea-AI Summary
TuHURA Biosciences (NASDAQ:HURA) reported 2025 results and a corporate update, highlighting a Phase 3 SPA-backed IFx-2.0 trial in first-line Merkel Cell Carcinoma, a completed $10.5 million acquisition of Kineta rights to TBS-2025, and planned clinical and preclinical milestones through 2027.
Financials show $3.6 million cash at 12/31/2025, R&D of $20.5M, G&A of $7.6M, net operating outflows of $27.7M, and $21.2M gross raised in 2025 financings.
AI-generated analysis. Not financial advice.
Positive
- Initiated Phase 3 SPA trial for IFx-2.0 in first-line MCC
- Completed acquisition of Kineta rights to TBS-2025 for $10.5 million
- Raised gross proceeds of $21.2 million in 2025 financings
Negative
- Cash and cash equivalents of $3.6M at December 31, 2025
- Net cash outflows from operations of $27.7M in 2025
- Research and development expenses rose to $20.5M in 2025
News Market Reaction – HURA
On the day this news was published, HURA declined 9.50%, reflecting a notable negative market reaction. Argus tracked a trough of -33.0% from its starting point during tracking. Our momentum scanner triggered 10 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $11M from the company's valuation, bringing the market cap to $108.69M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
HURA is up 3.47% while momentum peers PYXS, IOBT, and CGEN are down between -2.74% and -13.46%. Broader biotech peers in the watchlist mostly show gains, pointing to a stock-specific reaction to this earnings and pipeline update rather than a unified sector move.
Previous Earnings Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 14 | Q3 2025 earnings | Positive | +0.5% | Reported Q3 2025 results and progress on IFx-2.0 and VISTA programs. |
| Aug 14 | Q2 2025 earnings | Positive | +10.9% | Q2 2025 results plus Kineta acquisition and Phase 3 IFx-2.0 trial start. |
| May 15 | Q1 2025 earnings | Positive | +2.1% | Q1 2025 results, Phase 3 planning for IFx-2.0, and Kineta acquisition plan. |
| Apr 01 | FY 2024 results | Positive | -9.9% | Fiscal 2024 results with expanded pipeline and financing activities. |
Earnings and annual updates have usually seen modest positive or flat moves, with one notable selloff despite constructive operational progress.
Over the past year, TuHURA’s earnings and annual updates have highlighted steady advancement of IFx-2.0, acquisition and integration of Kineta’s VISTA antibody TBS-2025, and growing R&D investment. The Apr 1, 2024 FY 2024 update coincided with a -9.91% move, while Q1–Q3 2025 earnings on May 15, Aug 14, and Nov 14 saw smaller positive reactions. Today’s 2025 results extend this narrative with higher spend and clearer clinical timelines.
Historical Comparison
In the last four earnings or annual updates, HURA’s average move was about 0.88%. Today’s earnings and corporate update fit a pattern of generally modest price reactions to financial reports and pipeline progress.
Earnings releases from FY 2024 through Q3 2025 show a progression from planning IFx-2.0 Phase 3 and Kineta acquisition to executing the Phase 3 trial, integrating TBS-2025, and steadily increasing R&D investment to support multiple oncology programs.
Regulatory & Risk Context
An effective Form S-3 filed on Nov 3, 2025 registers up to $250,000,000 of mixed securities and a resale of up to 9,321,545 shares, including an ATM component of up to $50,000,000 as part of the base shelf. This provides flexibility for future primary financings and secondary sales by existing holders.
Market Pulse Summary
The stock moved -9.5% in the session following this news. A negative reaction despite the detailed 2025 update would fit past instances where shares fell on fundamentally constructive news, such as the -9.91% move after FY 2024 results. Rising R&D and operating cash outflows of $27.7 million in 2025, combined with existing shelf capacity of $250,000,000, leave ongoing financing risk. Prior patterns suggest that even strong clinical narratives have not always supported valuation in the short term.
Key Terms
special protocol assessment regulatory
accelerated approval regulatory
overall response rate medical
progression free survival medical
orphan drug designation regulatory
antibody drug conjugates medical
interventional radiology medical
myeloid-derived suppressor cells medical
AI-generated analysis. Not financial advice.
"2025 was a strong year of executing upon our goals, and we continue to move all our programs forward this year. As we progress our clinical development pipeline, we have strategically strengthened our clinical and drug development expertise with Craig Tendler, M.D., providing the strategic and operational services consistent with those of a Chief Medical Officer to oversee clinical development strategy and operations of the company's pipeline, including our VISTA inhibiting antibody, TBS-2025," said Dr. James Bianco, President and CEO of TuHURA Biosciences. "Craig brings a depth of experience that is invaluable to us as we look forward to several targeted key milestones in our VISTA program this year. Our IFx-2.0 Phase 3 study in front-line Merkel Cell Carcinoma (MCC) continues to enroll, and we now anticipate completing enrollment in mid-2027. Additionally, we continue to make important advancements toward preclinical proof-of-concept in our first-in-class immune modulating antibody drug conjugates (ADC) program and anticipate presenting new data at a scientific conference later this year."
Dr. Bianco continued, "We are grateful to have the unwavering support of our shareholders, who are committed to supporting our programs and realizing the potentially meaningful opportunity each one addresses."
Corporate Highlights
- Initiated a randomized Phase 3 Accelerated Approval Trial for IFx-2.0 in first line treatment of patients with advanced or metastatic Merkel Cell Carcinoma (MCC) as adjunctive therapy to Keytruda® (pembrolizumab). Phase 3 study trial being conducted under a Special Protocol Assessment (SPA) agreement with
U.S. Food and Drug Administration (FDA). Primary endpoint of Overall Response Rate (ORR) qualifies for accelerated approval process. Key secondary endpoint of Progression Free Survival (PFS) may satisfy the requirement for a post confirmatory trial, converting accelerated approval to regular approval. - Initiated Phase 1b/2a Study of IFx-2.0 as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for metastatic Merkel Cell Carcinoma of Unknown Primary Origin (MCCUP). Trial designed to evaluate the safety and feasibility of IFx-Hu2.0 in combination with Keytruda® when administered via Interventional Radiology (IR) in patients with deep- seated tumors without associated cutaneous tumors.
- Closed acquisition of Kineta gaining rights to TBS-2025, a novel VISTA inhibiting antibody, for
$10.5 million - Raised gross proceeds of
$21.2 million - Presented data demonstrating the Delta Opioid Receptor (DOR) as a new target in overcoming acquired resistance to immune checkpoint inhibitors at ASH. Selected for Oral Presentation by the Scientific Committee of American Society of Hematology new scientific evidence that DOR is expressed on tumor-associated Myeloid-Derived Suppressor Cells (MDSCs), and its inhibition decreases immune suppressing capabilities of MDSCs by downregulating expression of multiple genes associated with MDSC induced immunosuppression. Data also presented in the poster session demonstrated that the DOR is also expressed on tumor associated macrophages (TAMs) and DOR inhibition appears to reverse TAM mediated T cell suppression with the potential to overcome resistance to checkpoint inhibitors and other cancer immunotherapies.
Upcoming Targeted Milestones by Program
IFx-2.0 (Innate immune agonist)
- 1H 2026: Anticipate Orphan Drug Designation for IFx-2.0 in MCC
- 2H 2026: Anticipate preliminary data from the Phase1b/2a study of IFx-2.0 as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for metastatic Merkel Cell Carcinoma of Unknown Primary Origin (MCCUP)
- 2H 2027: Anticipate topline results from the Phase 3 accelerated approval trial of IFx-2.0 as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for advanced or metastatic MCC
TBS-2025 (VISTA inhibiting antibody)
- June 2026: Meeting with the FDA to discuss the development plan for TBS-2025 in NPM1 mut r/r AML
- 2H 2026: Anticipate initiation of Phase 1b/2 trial of VISTA in NPM1 mut r/r AML
Lead ADC Selection
- 1H 2026: Select lead ADC in AML
- 2H 2026: Expect to initiate ADC in vivo proof of concept (POC) studies
- 2H 2026: Anticipate POC data in humanized model of AML
- 2H 2026: Presentations at key scientific meetings
Summary of Financial Results for the Full Year 2025
Cash and cash equivalents of
Research and development expenses were
General and administrative (G&A) expenses were
Net cash outflows from operating activities were
Net cash flows from financing activities were
About TuHURA Biosciences, Inc.
TuHURA Biosciences, Inc. (Nasdaq: HURA) is a Phase 3 immuno-oncology company developing novel technologies to overcome primary and acquired resistance to cancer immunotherapy, two of the most common reasons cancer immunotherapies fail to work or stop working in the majority of patients with cancer.
TuHURA's lead innate immune agonist, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA has initiated a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) compared to Keytruda® plus placebo in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.
In addition to its innate immune agonist product candidates, TuHURA acquired TBS-2025 in its merger with Kineta Inc. on June 30, 2025. TBS-2025 is a VISTA inhibiting mAb moving into Phase 2 development in mutNPM1 r/r AML.
In addition, TuHURA is leveraging its Delta Opioid Receptor technology to develop first-in-class, bi-specific antibody drug conjugates targeting Myeloid Derived Suppressor Cells to inhibit their immune-suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.
For more information, please visit www.tuhurabio.com and connect with TuHURA on Facebook, X, and LinkedIn.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains certain "forward-looking statements" within the meaning of, and subject to the safe harbor created by Section 27A of the Securities Act, Section 21E of the Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These Forward-Looking Statements are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and other future conditions. In some cases, you can identify these statements by forward-looking words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "could," "should," "would," "project," "plan," "expect," "goal," "seek," "future," "likely," or the negative or plural of these words or similar expressions. You are cautioned that such statements are not guarantees of future performance and that actual results or developments may differ materially from those set forth in these forward-looking statements. Factors that could cause actual results to differ materially from these forward-looking statements are described in detail in our registration statements, reports and other filings with the SEC, which are available on TuHURA's website and at www.sec.gov.
The forward-looking statements and other information contained in this press release are made as of the date hereof, and TuHURA does not undertake any obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.
Investor Contact:
Monique Kosse
Gilmartin Group
Monique@GilmartinIR.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/tuhura-biosciences-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-a-corporate-update-302730804.html
SOURCE TuHURA Biosciences, Inc.